Skip to main content
Delfa

← All trials/NCT02823665

RecruitingPhase EARLY_1

The Effects of Bariatric Surgeries on Glucose Metabolism

Asset

Avexitide

Listed sites

2

Recruiting sites

2

Estimated enrollment

200

Study population

-

Eligibility highlights

•Healthy volunteers

Primary endpoint

-

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02823665
Org study ID20180070H
Secondary ID1R01DK105379-01

Timeline

Milestones

Study first posted2016-07-06estimated
Last update posted2025-09-09actual
Study start2015-07 (month precision)
Primary completion2026-08estimated (month precision)
Study completion2027-08estimated (month precision)

Assets

Investigational agents

Avexitide

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•Hypoglycemic RYGB patients with documented blood glucose level <50 mg/dl
•Asymptomatic individuals with bariatric surgery
•Healthy non-surgical patients with no personal history of diabetes
•Subjects must physically be able to come to our clinical research center Cedars-Sinai Medical Center

Exclusion criteria

•Active heart, lung, liver, gastrointestinal or kidney disease; unable to give informed consent; pregnancy; uncontrolled high blood pressure or high cholesterol; significant anemia (hemoglobin <11g/dL); prisoners or institutionalized individuals; type 2 diabetes mellitis; development of any serious medical or psychiatric illness during recruitment or studies;
•RYGB patients will be disqualified if they have gastric outlet obstruction or severe diarrhea.
•Healthy non-surgical patients with personal history of diabetes

For administration of atropine, the following exclusions also apply:

•History of glaucoma
•Uncontrolled hypertension (any subjects with BP>140/90 and history of dyslipidemia
•Taking any medication that might interact with atropine and cannot be stopped will be excluded from the study)
•Myasthenia gravis
•Brain pathology
•Enlarged prostate in men

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.